Since diabetes is an important component of NAFLD development and metabolic syndrome, the efficacy, safety and good tolerability make the GLP-1 agonist a suitable treatment tool for NAFLD. Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.